RESCUE-II Study Results Demonstrate Safety and Feasibility of the BASHIR™ Endovascular Catheter (BEC) in Treating Pulmonary Embolism (PE) On-The-Table (OTT)
New Britain, PA June 25, 2025 --( PR.com )-- NeThrombolex, Inc., a medical device manufacturer committed to advancing solutions for the treatment of arterial and venous thromboembolic diseases, announced the publication of the results from the RESCUE-II Study in JACC: Advances. The RESCUE-II Study was a single-center, prospective study evaluating the safety and feasibility of OTT pharmaco-mechanical lysis (PML) without postprocedural infusion when treating patients with acute intermediate-risk PE. 9 patients were enrolled and successfully treated with low dose r-tPA (4mg per pulmonary artery) using the BEC. At 48 hours, the mean RV/LV ratio decreased by 22.3%, and pulmonary artery obstruction, as measured by the Refined Modified Miller Index, was reduced by 29.2%. There were no major bleeding events, no deaths or serious adverse events through 30-day follow-up.
'This marks a significant milestone for our Company, as we are proud to contribute high quality evidence to the field and remain committed to advancing innovative treatments.' said Michael Cerminaro, President & CEO of Thrombolex. 'We would like to thank Senator Steve Santarsiero and the Department of Community and Economic Development of the Commonwealth of PA for their grant funding support of this important clinical research.'
'The RESCUE-II Study demonstrated encouraging safety and feasibility, while reinforcing the clinical value of this novel OTT protocol,' said, Dr. Vlad Lakhter, IC at Temple University Hospital. 'These results warrant further investigation in larger, multicenter trials like the RAPID-PE Study, which is currently enrolling patients.'
An independent data safety monitoring board adjudicated all clinical events for the RESCUE-II Study, while imaging data was assessed by an independent Core laboratory.
The publication is available online in JACC: Advances: https://www.sciencedirect.com/science/article/pii/S2772963X25002078
About Thrombolex, Inc.
Founded in 2016, Thrombolex is engaged in the design, development, and distribution of innovative endovascular catheters used in interventional procedures, particularly in pharmaco-mechanical lysis (PML) in patients who suffer from arterial and venous thromboembolic conditions. The Company is currently marketing eight (8) different FDA-cleared devices that are all based on the BASHIR™ Endovascular Catheter platform technology. For general inquiries, please contact Thrombolex at [email protected] or for more information about Thrombolex and its solutions, visit www.thrombolex.com.
Contact Information:
Thrombolex, Inc.
Tony Litwiller
(704) 408-0927
Contact via Email
www.Thrombolex.com
Read the full story here: RESCUE-II Study Results Demonstrate Safety and Feasibility of the BASHIR™ Endovascular Catheter (BEC) in Treating Pulmonary Embolism (PE) On-The-Table (OTT)
Press Release Distributed by PR.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
11 minutes ago
- Bloomberg
Federal Reserve Poised to Hand Wall Street a Big Gift
Wall Street is poised to receive a big gift courtesy of the Federal Reserve. The central bank unveiled plans to roll back an important capital rule that big banks have complained limits their ability to hold more Treasuries and act as intermediaries in the $29 trillion market. (The Fed's announcement confirmed proposed changes to the rule first reported by Bloomberg News last week.) The Fed board voted 5-2 on Wednesday to propose changes to what's known as the enhanced supplementary leverage ratio, which applies to the largest US banks—like Bank of America, JPMorgan and Goldman Sachs. The revisions would reduce holding companies' capital requirement under the ratio to a range of 3.5% to 4.5% from the current 5%. Their banking subsidiaries would see that requirement lowered to the same range from 6%.
Wall Street Journal
14 minutes ago
- Wall Street Journal
Is the Fed Ready for an AI Economy?
Federal Reserve presidents have been clear about their concerns regarding artificial intelligence's possible effects on productivity, banking customer service, and upheaval in the labor market. But the Fed may be ignoring another AI issue that could turn out to dwarf all others: AI's coming ability to create money and credit—and thereby determine the money supply in our economy.
Forbes
15 minutes ago
- Forbes
‘M3GAN 2.0' Reviews: Is AI Robot Sequel Programmed For Success?
M3GAN (Amie Donald, voiced by Jenna Davis) in "M3GAN 2.0." M3GAN 2.0 — the sequel to the 2022 horror hit starring Allison Williams — is new in theaters this week. Read on to find out what critics have to say about the movie. Directed by M3GAN filmmaker Gerard Johnstone, M3GAN 2.0 plays in Thursday previews before opening in theaters nationwide on Friday. The official summary for M3GAN 2.0 reads, 'Two years after M3GAN, a marvel of artificial intelligence, went rogue and embarked on a murderous (and impeccably choreographed) rampage and was subsequently destroyed, M3GAN's creator Gemma (Williams) has become a high-profile author and advocate for government oversight of A.I. "Meanwhile, Gemma's niece Cady (Violet McGraw), now 14, has become a teenager, rebelling against Gemma's overprotective rules. Unbeknownst to them, the underlying tech for M3GAN has been stolen and misused by a powerful defense contractor to create a military-grade weapon known as Amelia (Ivanna Sakhno), the ultimate killer infiltration spy. "But as Amelia's self-awareness increases, she becomes decidedly less interested in taking orders from humans. Or in keeping them around. With the future of human existence on the line, Gemma realizes that the only option is to resurrect M3GAN (Amie Donald, voiced by Jenna Davis) and give her a few upgrades, making her faster, stronger, and more lethal. As their paths collide, the original AI icon is about to meet her match.' M3GAN 2.0 also stars Brian Jordan Alvarez and Jen Van Epps, who return from the 2022 film as Gemma's tech team members Cole and Tess. New to the cast for the sequel are Aristotle Athari, Timm Sharp and Jemaine Clement. The review embargo for M3GAN 2.0 was lifted on Wednesday. As of the publication of this article, the film has earned a 62% 'fresh' rating from Rotten Tomatoes critics based on 61 reviews. RT's Critics Consensus and Popcornmeter score from verified user ratings is still pending. What Do Individual Critics Have To Say About 'M3GAN 2.0'? John Nugent of Empire Magazine is among the top critics on Rotten Tomatoes who gave M3GAN 2.0, writing, 'M3GAN 2.0 is more absurd, self-aware silliness: a riot of timely tech paranoia, with almost no horror but a ton of successful comedy. Slay, queen!' Robbie Colin of the Daily Telegraph (UK) also got a charge out of M3GAN 2.0, writing on RT, 'This uproarious (if not especially scary) sequel has the measure of the task at hand's silliness, and leans into it with infectious glee.' The film also received a 'fresh' rating on RT from Clarissa Loughrey of the Independent (UK), who writes, 'M3GAN 2.0 is, admittedly, a pretty bizarre conflagration of tones and ideas. But so were most of the Child's Play films ... and the rollercoaster effect of never quite knowing what genre [Gerard] Johnstone might pull from next is a key part of the fun.' On the flip side, David Fear of Rolling Stone gives M3GAN 2.0 a 'rotten' review on RT, writing, 'Her model is 2.0. The overbaked, underwhelming, narratively restless movie itself is 0.0 percent watchable.' David Rooney of The Hollywood Reporter also gives M3GAN 2.0 a 'rotten' review on RT, writing in his summary, 'A convoluted mishmash with shades of Terminator 2: Judgment Day, Mission: Impossible and the Austin Powers franchise. There are amusing moments reminiscent of the original, but in terms of tone and coherence, the movie loses its way.' Alison Foreman of IndieWire isn't a fan of M3GAN 2.0, either, writing in his 'rotten' review on RT, 'M3GAN's greatest asset was never her heart, but her lack of one. It's somewhat baffling, then, that she is easily the most likable character in a lineup of algorithmically hateable humans.' Rated PG-13, M3GAN 2.0 plays in Thursday previews before opening in theaters nationwide on Friday.
